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The currently available anti-Toxoplasma agents have serious limitations. This systematic
review was performed to evaluate drugs and new compounds used for the treatment
of toxoplasmosis. Data was systematically collected from published papers on the
efficacy of drugs/compounds used against Toxoplasma gondii (T. gondii) globally during
2006–2016. The searched databases were PubMed, Google Scholar, Science Direct,
ISI Web of Science, EBSCO, and Scopus. One hundred and eighteen papers were
eligible for inclusion in this systematic review, which were both in vitro and in vivo
studies. Within this review, 80 clinically available drugs and a large number of new
compounds with more than 39 mechanisms of action were evaluated. Interestingly,
many of the drugs/compounds evaluated against T. gondii act on the apicoplast.
Therefore, the apicoplast represents as a potential drug target for new chemotherapy.
Based on the current findings, 49 drugs/compounds demonstrated in vitro half-maximal
inhibitory concentration (IC50) values of below 1µM, but most of them were not
evaluated further for in vivo effectiveness. However, the derivatives of the ciprofloxacin,
endochin-like quinolones and 1-[4-(4-nitrophenoxy) phenyl] propane-1-one (NPPP) were
significantly active against T. gondii tachyzoites both in vitro and in vivo. Thus, these
compounds are promising candidates for future studies. Also, compound 32 (T. gondii
calcium-dependent protein kinase 1 inhibitor), endochin-like quinolones, miltefosine,
rolipram abolish, and guanabenz can be repurposed into an effective anti-parasitic with
a unique ability to reduce brain tissue cysts (88.7, 88, 78, 74, and 69%, respectively).
Additionally, no promising drugs are available for congenital toxoplasmosis. In conclusion,
as current chemotherapy against toxoplasmosis is still not satisfactory, development of
well-tolerated and safe specific immunoprophylaxis in relaxing the need of dependence
on chemotherapeutics is a highly valuable goal for global disease control. However,
with the increasing number of high-risk individuals, and absence of a proper vaccine,
continued efforts are necessary for the development of novel treatment options against
T. gondii. Some of the novel compounds reviewed here may represent good starting
points for the discovery of effective new drugs. In further, bioinformatic and in silico
studies are needed in order to identify new potential toxoplasmicidal drugs.
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INTRODUCTION
Toxoplasma gondii (T. gondii), an obligate intracellular, parasitic
protozoan, is the etiologic agent of toxoplasmosis. About 30–
50% of the world population is infected with the parasite, and
it is the most prevalent infection among humans (Tenter et al.,
2000; Flegr et al., 2014). Worldwide, over 1 billion people are
estimated to be infected with T. gondii (Hoffmann et al., 2012).
Its prevalence in some countries is high (e.g., Brazil, 77.5%;
Sao Tome and Principe, 75.2%; Iran, 63.9%; Colombia, 63.5%;
and Cuba, 61.8%) (Pappas et al., 2009). The annual incidence
of congenital toxoplasmosis was estimated to be 190,100 cases
globally (Torgerson and Mastroiacovo, 2013).
In the United States, the Centers for Disease Control and
Prevention (CDC) reported that 22.5% of the population 12
years and older have been infected with Toxoplasma with
1.1 million new infections each year, making it the second
most common cause of deaths due to foodborne diseases
(an estimated 327 deaths) and the fourth leading cause of
hospitalizations attributable to foodborne illness (an estimated
4428 hospitalizations). Also, an estimated 400–4000 infants are
bornwith congenital toxoplasmosis in theUnited States each year
(Jones et al., 2014).
T. gondii has three infectious stages of sporozoites (in oocysts),
tachyzoites (rapidly multiplying form), and bradyzoites (tissue
cyst form). Among them, tachyzoites are responsible for clinical
manifestations and the acute phase of the disease. They are
susceptible to the immune response of the host and to drug
action. The resistant cyst form of the parasite is resistant to both
the immune system and drugs (Hill and Dubey, 2002).
Acute toxoplasmosis in healthy individuals is usually
subclinical and asymptomatic, but may lead to chronic infection.
However, toxoplasmosis can lead to great morbidity and
mortality rates in imunocompromised or congenitally infected
individuals (Dubey and Jones, 2008; Ahmadpour et al., 2014).
In AIDS patients, presence of the parasite causes necrotizing
encephalitis and focal cerebral lesions in the central nervous
system (CNS) from primary or recrudescent infection. In
immunocompetent patients, latent toxoplasmosis occurs with
the formation of cysts principally in the CNS (Martins-Duarte
et al., 2006).
In the recent years, the development of well-tolerated
and safe specific immunoprophylaxis against toxoplasmosis is
a highly valuable goal for global disease control (Lim and
Othman, 2014). Immunotherapeutics strategies for improving
toxoplasmosis control could either be a vaccine which would
induce strong protective immunity against toxoplasmosis, or
passive immunization in cases of disease recrudescence. In the
last few years, much progress has been made in vaccine research
on DNA vaccination, protein vaccination, live attenuated
vaccinations, and heterologous vaccination; while there were few
candidates on passive immunization. New vaccine candidates
have been tested, including in particular proteins from T. gondii
ROP, MIC, and GRA organelles, multi-antigen vaccines, novel
adjuvants but until now the researches could not access to a
proper vaccine for prevention of toxoplasmosis in human (Zhang
et al., 2013, 2015).
The recommended drugs for treatment or prophylaxis
of toxoplasmosis are pyrimethamine and sulfadiazine.
Unfortunately, these drugs have side effects such as neutropenia,
severe drop of platelet count, thrombocytopenia, leucopenia,
elevation in serum creatinine and serum liver enzymes,
hematological abnormalities, and hypersensitivity reactions
(Bosch-Driessen et al., 2002; Silveira et al., 2002; Schmidt
et al., 2006). In addition, other drugs, such as azithromycin,
clarithromycin, spiramycin, atovaquone, dapsone, and
cotrimoxazole (trimethoprim-sulfamethoxazole), have been
used for clinical toxoplasmosis. However, these drugs are poorly
tolerated and have no effect on the bradyzoite form (Araujo and
Remington, 1992; Petersen and Schmidt, 2003; Serranti et al.,
2011).
In a clinical trial, 24% of sera positive women treated with
spiramycin and pyrimethamine plus sulfadoxine combination
delivered Toxoplasma infected infants in France (Bessières et al.,
2009). Spiramycin monotherapy can be effective during the early
stage of pregnancy to prevent prenatal transmission (Julliac
et al., 2010). More than 50% of patients treated with spiramycin
retained T. gondii DNA in blood and remained infected (Habib,
2008).
In recent years, studies have focused on finding safe drugs
with novel mechanisms of action against T. gondii. Accordingly,
there is an urgent need to evaluate new drugs based on novel and
innovative therapeutic strategies against T. gondii that are both
efficacious and nontoxic for humans (Rodriguez and Szajnman,
2012; Vanagas et al., 2012; Angel et al., 2013). Therefore, the
goal of the present systematic review was to retrieve published
studies related to in vitro and in vivo evaluation of drugs and
compounds for the treatment of toxoplasmosis (2006–2016) in
order to prepare comprehensive data for designingmore accurate
investigations in future.
METHODOLOGY
This review followed the preferred reporting items for systematic
reviews (PRISMA) guidelines (Moher et al., 2009).
Literature Search, Study Selection, and
Data Extraction
English databases, including PubMed, Science Direct,
Scopus, Google Scholar, ISI Web of Science, and EBSCO,
were systematically searched for papers on in vitro and
in vivo evaluation of anti-Toxoplasma activities of drugs and
compounds, published worldwide, from 2006 to 2016. The
keywords included were: “Toxoplasmosis,” “T. gondii,” “Anti-
Toxoplasma,” “Drug,” “Anticoccidial,” “Treatment,” “In vitro,”
“In vivo,” and “Compound.”
Papers written in English were selected. Gray literature and
abstracts of articles which were published in congresses were
not explored. In addition, in order to avoid missing any articles,
whole references of the papers were meticulously hand-searched.
Among English articles found with the mentioned strategies, full
text papers that used laboratory method both in vitro and in vivo
were included.
Frontiers in Microbiology | www.frontiersin.org 2 January 2017 | Volume 8 | Article 25
Montazeri et al. Anti-Toxoplasma Drugs and Compounds
Also, studies with at least one of the following criteria were
excluded: (1) studies that were not relevant; (2) articles not
available in English; (3) studies on treatments for ocular infection;
(4) articles that were of review or descriptive study type; (5)
articles which contained no eligible data; (6) case series reports;
(7) the data were duplicated from other studies or we were unable
to obtain them; (8) those that were on efficacy of anti-T. gondii
medicines in humans; and (9) any drug with an IC50 value >
10µM.
Data Collection
All the experimental studies that were carried out to evaluate
the efficacy of either drugs or compounds against T. gondii
both in vitro and in vivo were included, and replicates were
excluded. The inclusion criteria for selection of in vitro studies
were important information about medication used for the
experiments, type of cells used for culture, identification of
the Toxoplasma strain, laboratory methods used for assessing
drug activities, and main results comprising of the 50%
inhibitory concentration (IC50). We reported in vivo studies
used animal models, Toxoplasma strain, route of infection, the
treatment schedule (dosage, route of administration, duration
of treatment), the criteria for assessing drug activity (mainly
survival for acute toxoplasmosis, histology, and brain cyst
burdens for chronic infection), and the main results.
RESULTS
Analysis of the Included Literature
A total of 118 papers (83 studies in vitro, 59 in vivo, 27 both in
vitro and in vivo) published from 2006 to 2016, were included in
the systematic review. Figure 1 briefly shows the search process
in this systematic review article.
Mechanisms of Action
In the current systematic review, 80 clinically available drugs
(Table 1) and several new compounds with more than 39
pathways/ mechanisms of action were evaluated against T.
gondii in both in vitro and in vivo studies. Several target based
drug screens were also identified against T. gondii include
mitochondrial electron transport chain, calcium-dependent
protein kinase 1, type II fatty acid synthesis, DNA synthesis, DNA
FIGURE 1 | The PRISMA flow diagram of the search strategy, study selection, and data management procedure of in vitro and in vivo activities of
anti-Toxoplasma drugs and compounds (2006–2016).
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TABLE 1 | Clinically available drugs/compounds evaluated against T. gondii in vitro and in vivo studies.
Common clinical uses Drugs/compounds References
Antiprotozoal agents Bisphosphonates Baramee et al., 2006; Ferreira et al., 2006; Rajapakse et al., 2007; Strobl et al., 2007;
Leepin et al., 2008; Shubar et al., 2008; Liesen et al., 2010; Aquino et al., 2011; Franco
et al., 2011; Martins-Duarte et al., 2011; Chew et al., 2012; Asgari et al., 2013; Bilgin
et al., 2013; Gomes et al., 2013; Gaafar et al., 2014; da Silva et al., 2015;


























Antibacterial agents Sulfadiazine Meneceur et al., 2008; Costa et al., 2009; Barbosa et al., 2012; Payne et al., 2013;











Anticoccidial agents NPPPb Kul et al., 2013; Choi et al., 2014; Oz, 2014a,b
Diclazuril
Toltrazuril
Antihelminthic agents Niclosamide Fomovska et al., 2012; Galván-Ramírez et al., 2013
Nitazoxanide
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TABLE 1 | Continued
Common clinical uses Drugs/compounds References
Anticancer agents SAHAc Strobl et al., 2007; Portes Jde et al., 2012; Leyke et al., 2012; Barna et al., 2013; Kadri


















Immunomodulators agents Rolipram Afifi and Al-Rabia, 2015
Immunoregulatory agents Levamisole Köksal et al., 2016
Antipsychotic agents Aripiprazole Saraei et al., 2015
Antioxidant agents Resveratrol Bottari et al., 2015












Moodstabilizing agents Valproate Fond et al., 2014
Anti hypertensive agents Guanabenz Benmerzouga et al., 2015
Anti hypertensive and
irregular heart rate agents
Propranolol Montazeri et al., 2015, 2016
a2-hydroxy-3-(1′-propen-3-phenyl)-1,4-naphthoquinone.
b (4-nitrophenoxy) phenyl] propane one.
cSuberoylanilide hydroxamic acid.
replication, etc. (Table 2). Also, drugs/compounds with known
mechanisms of action on life stages of T. gondii are shown in
Figure 2. Our collective data indicated that many of the drugs/
compounds evaluated against T. gondii act on the apicoplast.
Therefore, the apicoplast represents as a potential drug target for
new chemotherapy.
The Investigated Strains
T. gondii has three main clonal lineages in population structure;
type I (including a highly virulent RH strain), Type II (including
ME49 and PRU, avirulent strains), and Type III (including
avirulent strains like NED), which is correlated with virulence
expression in mice (Howe and Sibley, 1995).
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TABLE 2 | Drugs/compounds with pathways/ mechanisms of action against T. gondii.
Pathway/mechanism of action Drugs/compounds References
Electron transport chain PHNQ6*a Baramee et al., 2006; Ferreira et al., 2006, 2012; Saleh et al.,
2007; Meneceur et al., 2008; Bajohr et al., 2010; Doggett et al.,








Sterol biosynthesis Novel quinuclidine (ER119884, E5700) Martins-Duarte et al., 2006
Synthesis of cholesterol Am80* Ihara and Nishikawa, 2014




Calcium-dependent protein kinase 1 1 NM-PP1* Sugi et al., 2011; Doggett et al., 2014; Moine et al., 2015b;
Vidadala et al., 2016Bumped Kinase Inhibitor 1294*
Imidazo [1,2-b] pyridazines*
Compound 32*
Human mitogen-activated protein kinase Pyridinylimidazole* Wei et al., 2007
Imidazopyrimidine*
Nucleoside triphosphate hydrolase (NTPase) 2-(Naphthalene-2-γlthiol)-1H indole* Asgari et al., 2013, 2015
Isoprenoid pathway 2- alkylaminoethyl- 1,1- bisphosphonic acids* Shubar et al., 2008; Szajnman et al., 2008; Li et al., 2013
Newly synthesized bisphosphonates*
Atorvastatin*
Type II fatty acid synthesis Thiolactomycin* Martins-Duarte et al., 2009; Tipparaju et al., 2010; El-Zawawy
et al., 2015a,b53 novel compounds*
Inhibitors of enoyl reductase
Triclosan and triclosan liposomal*
Protein synthesis Azithromycin* Costa et al., 2009; Franco et al., 2011; Chew et al., 2012; Zhou




Disappearance of the Apicoplast Quinoline derivatives* Smith et al., 2007; Kadri et al., 2014
(MC1626, quinoline, 8-hydroquinoline and B23)






DNA synthesis Metronidazole* Liesen et al., 2010; Chew et al., 2012; Gomes et al., 2013
Phenylsemicarbazone*
(Continued)
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TABLE 2 | Continued





Cyclic AMP signaling pathways Rolipram* Afifi et al., 2014; Afifi and Al-Rabia, 2015
Post-translational modification by N-linked
glycosylation of proteins
Tunicamycin* Luk et al., 2008
Membrane permeability Novel diamidine analog* Leepin et al., 2008





Micronemal secretion pathway, cysteine
protease
Peptidyl vinyl sulfone compounds* (LHVS and
ZL3VS)
Teo et al., 2007
Immuno-regulatory Levamisole* Köksal et al., 2016
Translational control Guanabenz* Payne et al., 2013; Benmerzouga et al., 2015; Jain et al., 2015
Fusidic acid
Halofuginone*
DNA gyrase activity, transcription Enrofloxacin Barbosa et al., 2012; Martins-Duarte et al., 2015
Ciprofloxacin derivatives*
Thioredoxin reductase Auranofin Andrade et al., 2014
Topoisomerases I and II HSP90 protein Harmane, norharmane, and harmine Alomar et al., 2013
Metabolism of neurotransmitters in the brain Resveratrol Bottari et al., 2015
Effect on the liver biochemical parameters ATT-5126 and KH-0562 Choi et al., 2014
Vascular ATP synthase subunit C and/or
methyltransferase
NPPP Choi et al., 2015
Sterol biosynthesis enzyme-sterol methyl
transferase.
22, 26-azasterol and 24, 25-(R, S)-
epiminolanosterol
Martins-Duarte et al., 2011
Downregulates expression of serine/threonine
protein phosphatase
Diclazuril Oz, 2014a,b
Ergosterol synthesis Fluconazole Martins-Duarte Edos et al., 2008; Martins-Duarte et al., 2013
Itraconazole
Interruption of mitosis Trifluralin Wiengcharoen et al., 2007
Oxidative phosphorylation Niclosamide Fomovska et al., 2012
Apocynin-dependent pathway NSC3852 Strobl et al., 2009
Phospholipid metabolism Miltefosine Eissa et al., 2015
(Continued)
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TABLE 2 | Continued
Pathway/mechanism of action Drugs/compounds References
Quinone oxidoreductase expression Nitaxozanide Galván-Ramírez et al., 2013
Kinase inhibitors Small-molecules Kamau et al., 2012
Tyrosine kinase Gefitinib Yang et al., 2014
Crizotinib
Adenosine kinase in the purine salvage
pathways
N6-benzyladenosine analog* Kim et al., 2007; Szajnman et al., 2008
Purine nucleoside phosphorylase 3-(thiophen-2-yl)-1,2,4-triazole-5-thione Dzitko et al., 2014b
Damage on the microneme proteins 7-nitroquinoxalin-2-ones (VAM2-2) Fernández et al., 2016





In vitro and in vivo screening methods were used of type I
T. gondii (mostly RH strain; 76 studies in vitro, and 36 in vivo).
Because type I RH strain is highly virulent in mice, causing 100%
mortality, but types II and III are relatively less virulent. Although
in some studies, ME49 (7 studies in vitro, and 17 in vivo),
Prugniaud, EGS, and VEG strains were used, which showed that
the outcome of infections depends on the challenge dose and on
the genotype of the host (Szabo and Finney, 2016). Details about
the investigated strains in vitro and in vivo are shown in Tables 3,
4, respectively.
Cell Culture
The cell cultures used in in vitro studies were mostly human
foreskin fibroblast (HFF; 39 studies), LLCMK2 (12 studies),
Vero (11 studies), Hela (6 studies), mouse macrophage cell line
(J774A.1) (5 studies), and MRC-5 (2 studies; Table 3).
Laboratory Animals
T. gondii can infect most warm-blooded animals, and is studied
in different animal models depending on the nature of the
investigation (Szabo and Finney, 2016). The animal model used
in studies was mostly mice (16 studies BALB/c and 19 studies
Swiss-Webster). In murine models of acute toxoplasmosis, some
medicines were protective even when administered at low
dosages. But some drugs despite of their excellent in vitro
activity were poorly protective in murine models with acute
toxoplasmosis (Payne et al., 2013).
Diagnostic Tests and Evaluation Methods
The present review outlines the results of in vitro screening
methods including morphological assay, incorporation of [3H]
uracil assay, plaque assays, enzyme-linked immunosorbent assay
(ELISA), colorimetric micro titer assay (b-galactosidase assay),
flow cytometric quantification assay, and cell viability assay.
Numerous versions of fluorescent proteins have been expressed
in T. gondii (Kim et al., 2001). The reporter genes used in vitro
and in vivo studies were the green fluorescent protein (GFP) and
yellow fluorescent protein (YFP). Parasites expressing fluorescent
proteins can also be analyzed and sorted by flow cytometry. This
technology used for drugs screening in 10 studies.
Details about the diagnostic methods and drug dosage under
in vivo conditions are shown in Table 4. Also, a comprehensive
list of drugs/compounds evaluated against T. gondii with regard
to IC50 is illustrated in Table 5.
DISCUSSION
The aim of this systematic review was to investigate the
in vitro and in vivo effects of anti-Toxoplasma drugs and
synthetic compounds, from 2006 to 2016. The current anti-T.
gondii chemotherapy is deficient; as it is not well-tolerated by
immunocompromised patients and cannot completely eradicate
tissue cysts produced by the parasite (Rodriguez and Szajnman,
2012). Therefore, developing new, safe, effective, and well-
tolerated drugs with novel mechanisms of action could be a
global priority (Lai et al., 2012). An ideal drug for prophylaxis
and/or treatment of toxoplasmosis would show effective
penetration and concentration in the placenta, transplacental
passage, parasiticidal properties vs. the different parasitic stages,
penetration into cysts, and distribution in the main sites. No
available drug fulfills these criteria (Derouin et al., 2000; Montoya
and Liesenfeld, 2004).
Thus, the findings of the present systematic review article
encourage and support more accurate investigations for future
to select new anti-Toxoplasma drugs and strategies in designing
new targets with specific activity against the parasite.
Activities of Anti-Toxoplasma Clinically
Available Drugs
With growing parasite resistance to therapeutic drugs
and in the absence of a vaccine, to increase the
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FIGURE 2 | Drugs/compounds with known mechanisms of action on life stages of T. gondii, tachyzoites (T), and bradyzoites (B). 1, apical end; 2, Cell
membrane; 3, microneme; 4, cytosol; 5, endoplasmic reticulum; 6, core; 7, mitochondria; 8, apicoplast.
effectiveness of drugs, various changes have been made in
construction of the clinically available medicines. Thus,
the activity of new formulations of clinically available
drugs against T. gondii should be evaluated to find
alternative treatments for toxoplasmosis (da Cunha et al.,
2010).
Interestingly, encapsulation of pyrimethamine improved the
efficacy and tolerability of this drug against acute toxoplasmosis
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TABLE 5 | A comprehensive list of drugs/compounds evaluated against T. gondii with regard to IC50.
Drug IC50 (µM) References
<1 1–5 5–10





2d, 2e, 2f Baramee et al., 2006
SAHAa, SBHAb, Scriptaid,
Trichostatin A






RWJ67657, (ME49 strain) SB202190 SB203580 Wei et al., 2007
SB203580
RWJ68198, (ME49 strain) RWJ68198, (RH strain)
RWJ67657, (RH strain)
1-hydroxy-2-dodecyl-4(1H) quinolone + Saleh et al., 2007
Fluorine-containing aryloxyethyl
thiocyanate derivatives
Compound 1, 3, 9 Compound 10 Liñares et al., 2007
Novel diamidine analog + Leepin et al., 2008
Pyrimethamine, sulfadiazine,
atovaquone
+ Meneceur et al., 2008
Novel triazine JPC-2067-B + Mui et al., 2008
2-alkylaminoethyl-1,1-bisphosphonic
acids
Compound 19 Compound 14, 17 Szajnman et al., 2008
Itraconazole + Martins-Duarte Edos et al., 2008
Thiolactomycin analog Compound 5, 6 Compound 2 Martins-Duarte et al., 2009
Fluconazole (FLZ) FLZ (48 h) FLZ (24 h) Martins-Duarte et al., 2010
1-Hydroxy-2-Alkyl-4(1H) Quinolone
derivatives
+ Bajohr et al., 2010
Haloperidol, clozapine, fluphenazine,
trifluoperazine, thioridazine
+ Goodwin et al., 2011
Novel azasterols Compound 3 (48 h) Compound 1 (48 h), 2, 3 (24 h) Compound 1 (24 h) Martins-Duarte et al., 2011
Endochin-like quinolones + Doggett et al., 2012
Pterocarpanquinone + Portes Jde et al., 2012
New naphthoquinones (QUI),
an alkaloid




+ Kropf et al., 2012
Fuconazole combined with
sulfadiazine and pyrimethamine
Pyrimethamine + Martins-Duarte et al., 2013
(Continued)
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TABLE 5 | Continued
Drug IC50 (µM) References
<1 1–5 5–10
Antipsychotic drugs and valproate Fluphenazine Zuclopenthixol Fond et al., 2014
Thioridazine
Fusidic acid + Payne et al., 2013
Ivermectin and sulphadiazine Ivermectin Sulphadiazine Bilgin et al., 2013
Novel ruthenium
complexes,(compounds 16 and 18)
+ Barna et al., 2013
Auranofin + Andrade et al., 2014
6-Trifluoromethyl-2-thiouracil + Choi et al., 2014
200 drug-like, 200 probe-like
compounds of Malaria Box







A 11, A14, A18, B11,









N-oxide hydrate A7, B18
Bumped Kinase Inhibitor 1294 + Doggett et al., 2014
Salicylanilides 3i, 3j, 7a, 14a, 14b Fomovska et al., 2012
Antiretroviral compounds Atazanavir Fosamprenavir Monzote et al., 2013
Ritonavir Nelfinavir
Saquinavir
Spiroindolone + Zhou et al., 2014
Ciprofloxacin derivatives Compound 2, 5 Compound 4 Dubar et al., 2011
Thiazolidin-4-one derivatives 12A 27, 34 A 36 A D’Ascenzio et al., 2014
N6-benzyladenosine analog Compound 11 e, g, j, n, o,
q, u, v
Kim et al., 2007
Naphthoquinone derivative LQB151 (48 h) LQB94 da Silva et al., 2015
LQB151 (24 h)
LQB150 (24, 48 h)
Oryzalin analogs Compound 6a, h, i, 14a,
18a, b, c
Compound 6b, g, j, I, n, 12 Compound 6m, 14b Endeshaw et al., 2010
94 compounds + Dittmar et al., 2016
6-(1,2,6,7-tetraoxaspiro[7.11]
nonadec-4-yl)hexan-1-ol (N-251)
+ Xin et al., 2016
aSuberoylanilide hydroxamic acid.
bSuberic bishydroxamic acid.
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in mice and can be considered as an alternative for reducing
the dose and side effects of pyrimethamine (Pissinate et al.,
2014). Recently, researchers reported that computational analysis
of biochemical differences between human and T. gondii
dihydrofolate reductase enabled the design of inhibitors with
both improved potency and selectivity against T. gondii (Welsch
et al., 2016). El-Zawawy et al. reported that incorporating
triclosan into in the lipid bilayer of liposomes allowed its use
in lower doses, which in turn, reduced its biochemical adverse
effects (El-Zawawy et al., 2015b). In another study, sodium
dodecyl sulfate (SDS)-coated atovaquone nanosuspensions
(ANSs) considerably increased the therapeutic efficacy against
experimentally reactivated and acquired toxoplasmosis by
improving passage of gastrointestinal and blood-brain barriers.
Accordingly, coating of ANSs with SDS may improve the
treatment of toxoplasmic encephalitis and other cerebral diseases
(Shubar et al., 2011).
Also, various studies showed that a number of drugs were
investigated for the mechanisms of action summarized in Table 2
and Figure 2. One study discussing the metabolic differences
between the host and the parasite noted that dihydrofolate
reductase, isoprenoid pathway, and T. gondii histone deacetylase
are promising molecular targets (Rodriguez and Szajnman,
2012).
Novel triazine JPC-2067-B (4, 6-diamino-1, 2-dihydro-
2, 2-dimethyl-1-(3′(2-chloro-, 4-trifluoromethoxyphenoxy)
propyloxy)-1, 3, 5-triazine), the anti-folate medicines, is highly
effective against T. gondii with an IC50 of 0.02µM, which is
more efficacious than pyrimethamine and has in vitro cidal
activity. Additionally, pro-drug JPC-2056 (1-(3′-(2-chloro-4-
trifluoromethoxyphenyloxy) propyl oxy)-5-isopropylbiguanide)
is effective in vivo when administered orally (Mui et al., 2008).
Moreover, histone deacetylase is potentially a very important
drug target in T. gondii, since scriptaid and trichostatin A had
the highest effect against T. gondii tachyzoite proliferation with
the IC50 of 0.039 and 0.041µM, respectively (Strobl et al., 2007).
For promising anti- T. gondii drugs/compounds, assessment
of their ability to control parasite growth is a key step in drug
development (McFarland et al., 2016).
A large number of research papers suggested that
the apicoplast represents a potential drug target for new
chemotherapy, as it is essential to the parasite and it is absent in
host cells. Functions of the apicoplast include fatty acid synthesis,
protein synthesis, DNA replication, electron transport, and heme
biosynthesis (Yung and Lang-Unnasch, 2004). Some of the drugs
evaluated against T. gondii are shown to act in the apicoplast
such as thiolactomycin, triclosan (TS), azithromycin, fusidic
acid, ciprofloxacin, and quinoline derivatives (Costa et al., 2009;
Martins-Duarte et al., 2009, 2015; Payne et al., 2013; Kadri et al.,
2014; El-Zawawy et al., 2015b).
In T. gondii, FAS-II enzymes are present in the apicoplast
and are essential for its survival. The key enzyme in this
process is the ENR enzyme, which is not found in mammals
(Surolia and Surolia, 2001). This enzyme catalyzes the last
reductive step of the type II FAS pathway. The TS, which
inhibits type II FAS, significantly reduced mice mortality,
parasite burden, as well as viability and infectivity of tachyzoites
and cysts harvested from infected treated mice and their
brains. Accordingly, TS is proved as an effective, promising,
and safe preventive drug against acute and chronic murine
toxoplasmosis. Liposomal formulation of TS enhanced its efficacy
and allowed its use at a lower dose (Surolia and Surolia, 2001;
El-Zawawy et al., 2015a,b). Among apicoplast pathways, DNA
replication is an important potential chemotherapeutic target.
Fluoroquinolones are the known DNA replication inhibitors that
target prokaryotic type II topoisomerases (Collin et al., 2011). In
two studies, researchers showed that derivatives of the antibiotic
ciprofloxacin, a fluoroquinolone, are active against T. gondii
tachyzoites both in vitro and in vivo (Neville et al., 2015). While
all mice treated with ciprofloxacin died by day 10 post-infection,
some mice treated with ciprofloxacin derivatives remained alive
for at least 60 days, suggesting that ciprofloxacin derivatives
cured T. gondii infection in treated mice (Dubar et al., 2011;
Martins-Duarte et al., 2015).
Anti-Toxoplasma Activities of New
Synthetic Compounds
There are numerous reports on efficacy of many new synthetic
compounds with a focus on identifying drug candidates with
innovative and acceptable profiles against T. gondii. The anti-
coccidial effect of 1-[4-(4-nitrophenoxy) phenyl] propane-1-one
(NPPP), a synthetic compound, was studied both in vitro and
in vivo. Treatment with NPPP showed anti-Toxoplasma activity
in vitro with a lower EC50 value than pyrimethamine. In ICR
mice infected with T. gondii, oral administration of NPPP for
4 days showed statistically significant anti-Toxoplasma activity
with lower number of tachyzoites than those of the negative
control (Choi et al., 2015).
In a study by Kadri et al. anti-Toxoplasma properties of
58 newly synthesized quinoline compounds were evaluated.
A significant improvement in anti-Toxoplasma effect among
quinoline derivatives was detected in B11, B12, B23, and B24.
Among these compounds, B23 was the most effective compound
with the IC50 value of <1µM, displaying its anti-Toxoplasma
effects and ability to cause the disappearance of the apicoplast
(40–45% of the parasites lost their apicoplasts; Kadri et al., 2014).
In a study by Boyom et al. the strategy adopted was to
repurpose the open access Malaria Box to identify chemical
series active against T. gondii. The results showed that the most
interesting compound was MMV007791, a piperazine acetamide,
which has an IC50 of 0.19µM. This compound is novel for its
anti-Toxoplasma activity, and of course, further studies on the
rates and mechanisms of compound action will elucidate these
considerations (Boyom et al., 2014).
Tetraoxanes, anti-cancermolecules, were tested in vivo against
T. gondii. Subcutaneous, administration of a 10mg/kg/day dose
of derivative 21, for 8 days allowed the survival of 20% of infected
mice, demonstrating the high potential of tetraoxanes for the
treatment of T. gondii (Opsenica et al., 2015).
In another study by Moine et al. researchers evaluated
in vitro anti-T. gondii activity of 51 compounds with a
biphenylimidazoazine scaffold. Eight of these compounds
displayed highly potent activity against T. gondii growth in vitro,
Frontiers in Microbiology | www.frontiersin.org 24 January 2017 | Volume 8 | Article 25
Montazeri et al. Anti-Toxoplasma Drugs and Compounds
with 50% effective concentration (EC50) below 1mM, without
demonstrating cytotoxic effects on human fibroblastic cell at
equivalent concentrations. However, these compounds have to be
evaluated in animal models so as to confirm their in vivo activity
(Moine et al., 2015a).
Several pathways were characterized and shown to differ
significantly from those of the mammalian host cells, thus,
revealing an attractive area for therapeutic intervention.
1-Hydroxy-2-Alkyl-4 (1H) quinolone derivatives inhibit the
fourth step of the essential de novo synthesis of pyrimidine, which
uses ubiquinol reduction as an electron sink for dihydroorotate
oxidation (Saleh et al., 2007). Also, newly synthesized
bisphosphonates interfere with the mevanolate pathway,
which leads to the synthesis of sterols and polyisoprenoid
compounds that are important for parasite survival (Shubar
et al., 2008).
Interestingly, Kamau et al. identified novel kinases that are
integral to essential pathways, elucidating their mechanism of
action and ultimately, identifying new drug targets (Kamau et al.,
2012). In that study, 527 compounds were evaluated in vitro;
also, they assessed the impact of the inhibitory compounds
C1, C2, C3, and C5 in mouse models of toxoplasmosis. C2
was found quite effective in decreasing the parasite burden and
increasing mice survival. These results should be considered
with caution, since there are a number of factors are at
play in whether a compound will be in vivo effective, such
as solubility in vivo, access to different tissues, and host
metabolic processes (Kamau et al., 2012). In a recent study,
Dittmar et al. screened a collection of 1,120 compounds,
94 of which were blocked parasite replications with IC50 of
<5µM. These data suggest that tamoxifen restricts Toxoplasma
growth by inducing xenophagy or autophagic destruction of
this parasite (Dittmar et al., 2016). According to a new study,
in silico screening is useful, particularly in the identification of
molecular targets in the laboratory. Fernandez et al. synthesized
VAM2 compounds (7-nitroquinoxalin-2-ones), based on the
design obtained from an in silico prediction with the software
TOMOCOMD-CARDD. From the group of VAM2 compounds,
Fernandez et al. chose VAM2-2 with an IC50 of 3.3µM
against T. gondii. However, more studies are required to
evaluate its effect on the cysts formed by of the parasite
and in animal models of toxoplasmosis (Fernández et al.,
2016).
Activity of Drugs, Compounds, and
Combined Therapy against Cysts
An ideal drug against toxoplasmosis should not only be effective
against the proliferative stage of the parasite but also exert
dual activity against the tissue cyst stage and penetration
into cysts (Benmerzouga et al., 2015). Currently, there is no
approved therapy that eliminates the tissue cysts responsible for
chronic infection (Innes, 2010). Derouin reported that among
the drugs commonly used in humans, only atovaquone and
azithromycin were found effective after long-term incubation.
Besides, arpinocid-N-oxyde, an anticoccidial for veterinary use,
was efficient at a high dosage (Derouin, 2005).
Recently, investigators have focused on guanabenz for in vivo
studies, as guanabenz inhibitor of eIF2a dephosphorylation, is
already an food and drug administration (FDA) approved drug
and has excellent solubility with good penetration into the CNS.
The results of that study show that guanabenz (5mg/kg/day) not
only protects mice against acute toxoplasmosis, but also reduces
69% of the number of brain cysts in chronically infected animals.
This finding suggested that guanabenz can be repurposed into
an effective antiparasitic with a unique ability to diminish tissue
cysts in the brain (Benmerzouga et al., 2015).
Another study showed that miltefosine had no efficacy
in controlling acute toxoplasmosis after 5 days of treatment;
however, a 15-day treatment against the established chronic
stage led to a 78% reduction of cysts in the brain. Additionally,
the remaining cysts were noticeably smaller upon microscopic
examination, suggesting that the drug effectively penetrates the
blood-brain barrier, and that extension of treatment time may
produce greater effects (Eissa et al., 2015).
In another study by Maubon et al. FR235222 and its
derivatives were identified as new lead compounds for use against
acute and chronic toxoplasmosis both in vitro and in vivo. In vivo
experiments indicated that FR235222, as a histone deacetylase
inhibitor, is able to access the bradyzoites within the cyst. The
ability of FR235222 to permeate the membrane wall is a major
advantage for crossing the blood-brain barrier and CNS tissue,
where Toxoplasma cysts are located. This opens a promising way
to develop drugs that are selective against Toxoplasma and those
that have sterilizing activity, especially in patients with cysts, who
are at risk for reactivating acute toxoplasmosis (patients with
HIV infection, hematological malignancies, or transplantation).
Still, effectiveness of FR235222 against chronically infected mice
remains to be directly demonstrated in vivo (Maubon et al.,
2010).
In a new study Vidadala et al. identified compounds 32
(T. gondii calcium-dependent protein kinase 1 inhibitor) a
promising lead for the development of a new antitoxoplasmosis
therapy. Compounds 32 is CNS-penetrant and highly effective in
acute and latent mousemodels of T. gondii infection, significantly
reducing brain cysts by 88.7% (Vidadala et al., 2016).
Many studies reported anti- Toxoplasma effects of different
drugs combination with novel compounds. The compound
2-hydroxy-3-(1′-propen-3-phenyl)-1, 4-naphthoquinone
(PHNQ6), (50mg/kg/day) combined with sulfadiazine showed
reduction or elimination of brain cysts in vivo (Ferreira et al.,
2006). In another study that coadministered spiramycin
and metronidazole, spiramycin, did not reach effective
concentrations in the brain due to the presence of the eﬄux
transporters multidrug-resistant protein 2, and P-glycoprotein.
Metronidazole increased brain penetration of spiramycin,
causing a significant reduction of T. gondii brain cysts, with
potential clinical translatability for chronic toxoplasmosis
treatment. According to the reports, combination therapy leads
to faster recovery, less relapse, lower doses of drugs, and fewer
side effects of the disease. Furthermore, such combinations are
highly promising to develop a drug that is able to eliminate the
cyst stage of the parasite, and thus, efficiently impairs relapse of
the disease (Chew et al., 2012; Martins-Duarte et al., 2013).
Frontiers in Microbiology | www.frontiersin.org 25 January 2017 | Volume 8 | Article 25
Montazeri et al. Anti-Toxoplasma Drugs and Compounds
Activity of Drugs against Congenital
Toxoplasmosis
In pregnant women, current toxoplasmosis treatment is based
on the administration of spiramycin or a drug combination such
as sulphadiazine-pyrimethamine-folinic acid (SPFA) in cases of
confirmed fetal infection. However, these drugs are not well-
tolerated and present many adverse effects due to their toxic
effects to the host (Degerli et al., 2003).
Degerli et al. evaluated the effectiveness of azithromycin,
artemisia annua infusion, spiramycin, and SPFA in Calomys
callosus, such as model of congenital toxoplasmosis. The results
demonstrated that the treatment of pregnant C. callosus with
azithromycin was effective for inhibiting the vertical transmission
of T. gondii ME49 strain, suggesting that it may be an
alternative drug of choice for the treatment of congenital
infection, since it is able to inhibit fetal infection and offers
new perspectives for the treatment of congenital toxoplasmosis.
Azithromycin is one of the new generation macrolides with
numerous advantages. Mechanism of action of azithromycin is
based on the inhibition of protein synthesis in both T. gondii
tachyzoite and bradyzoite stages (Degerli et al., 2003), but it may
present limited effectiveness against T. gondii, requiring high
drug concentrations (Costa et al., 2009). In another study, Oz
et al. reported that combined atovaquone and diclazuril therapy
is a novel synergistic prophylactic and therapeutic approach
to fetal maternal toxoplasmosis (Oz, 2014a). Atovaquone,
an inhibitor of mitochondrial electron-transport processes,
is an FDA-approved toxoplasmosis therapy but not for use
in congenital toxoplasmosis treatment (Oz, 2014a). Another
compound, diclazuril, and its related benzeneacetonitriles have
long been used in the treatment and prevention of poultry
and livestock coccidiosis. In addition, it is known to be
a safe compound at therapeutic dose levels (Assis et al.,
2010).
Adverse Effects of Drugs
However, anti-Toxoplasma effects of drugs/compounds were
reported in many trials, but prednisolone increased the number
of tachyzoites and bradyzoites in immunosuppressed infected
mice (Puvanesuaran et al., 2012). In addition, betamethasone can
escalate the invasion of tachyzoites, in cell culture. It could be
suggested that patients under prolonged use of betamethasone
and prednisolone should be protected against T. gondii infection.
Also, if individuals receiving betamethasone are infected with T.
gondii, interferon-gamma may be used to reduce the invasion of
tachyzoites (Ghaffarifar et al., 2006).
CONCLUSIONS
As current chemotherapy against toxoplasmosis is still not
satisfactory, the development of well-tolerated and safe specific
immunoprophylaxis in relaxing the need of dependence
on chemotherapeutics is a highly valuable goal for global
disease control. Immunotherapeutics strategies for improving
toxoplasmosis control could either be a vaccine which would
induce strong protective immunity against toxoplasmosis,
or passive immunization in cases of disease recrudescence.
However, with the increasing number of high-risk individuals,
such as immunocompromised patients, and absence of a proper
vaccine, continued efforts are necessary for the development of
novel treatment options against T. gondii. Some of the novel
compounds reviewed here may represent good starting points
for the discovery of effective new drugs. In further bioinformatic
and in silico studies are needed in order to identify new potential
toxoplasmicidal drugs.
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